Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma
December 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improvements in children and adolescents with high-risk relapsed or refractory anaplastic large cell lymphoma, provide more insight into how to treat this population.
AR Inhibitors Lead to Higher Fall/Fracture Risk in Older Men With Prostate Cancer
December 17, 2020 - Androgen receptor inhibitor–therapy is associated with an increased risk of falls and fractures in patients with prostate cancer. However, since it has shown improvement in overall survival, the benefits may outweigh the risk.
Nivolumab/Ipilimumab Combo Shows Antitumor Activity in Metastatic Uveal Melanoma
December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.
Sequence of ADT With Radiation Is Crucial for Prostate Cancer Treatment
December 15, 2020 — The sequence in which hormonal therapy is given to men with localized prostate cancer should be considered as it can significantly affect outcomes.
Gene Expression Testing Varies Substantially by Region for Prostate Cancer
December 10, 2020 — Despite gene expression tests helping health care professionals make optimal treatment decisions, testing varies by region for men with prostate cancer and could be related to socioeconomic status and patterns of prostate cancer care.
HAIC Shows Better Efficacy and Safety in Unresectable HCC Versus Standard of Care
Overall survival was significantly improved in patients who received hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization.
How a NSCLC Pioneer Helped Unravel the Mysteries of EGFR
A 2018 Giants of Cancer Care award winner for Lung Cancer, Bruce E. Johnson, MD, has helped define the genomic era in lung cancer care. His notable contributions include characterizing the role that EGFR mutations play in non–small cell lung cancer.
Breast Cancer Surgery Choice May Affect Quality of Life in Younger Patients
Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.
Team Spirit Guides Gandara in Personalizing Care
David R. Gandara, MD, has pioneered groundbreaking therapies in lung cancer treatment through his leadership of interdisciplinary teams of oncologists, pharmacologists, molecular biologists, and statisticians.
ASCO and ESMO Value Frameworks May Be Beneficial in Determining Best Maintenance Therapies for Ovarian Cancer
To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.
Low Body Weight, Platelet Counts Predict Niraparib Dose Reductions for Ovarian Cancer
Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Checkpoint Inhibitors Induce Higher Rate of Adverse Events in Recurrent Ovarian Cancer
The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.
How Elbow Grease and Inspiration Forged a Winning Career
He was once laughed at for pouring his talent into the “reviled” field of oncology, but Larry Norton, MD, said he was driven by his passion to learn about cancer.
Frontline Brentuximab Vedotin With AVD Bests ABVD for Advanced HL
The phase III ECHELON-1 study in Hodgkin lymphoma compared the use of A+AVD with standard chemotherapy of doxorubicin, bleomycin, vinblastine, and dacarbazine.
Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCL
Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.
Study Offers Insight Into Age-Specific Breast, Ovarian Cancer Risk for BRCA-Positive Women
Researchers have yet to determine the degree to which harboring a BRCA1 or BRCA2 mutation raises a woman’s lifetime risk of developing breast and ovarian cancer.
Fear of Recurrence and Anxiety Lowered in Cancer Survivors After Psychological Intervention
Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.
Tripathy Offers Insights on Future of Breast Cancer From SABCS, ASCO
The 34th Annual Miami Breast Cancer Conference® featured a recap of significant research from the 2016 ASCO Annual Meeting and the 2016 San Antonio Breast Cancer Symposium.
Breast Density Surpasses Other Risk Factors in Development of Breast Cancer
High breast density surpasses other known risk factors for developing breast cancer, including family history of the disease, personal history of benign lesions, and later-in-life childbirth, according to the results of a study published in JAMA Oncology.
President Obama Signs 21st Century Cures Act
President Barack Obama signed the 21st Century Cures Act into law today, earmarking $6.3 billion over 10 years for advancements in precision medicine development, brain research, heroin and prescription drug abuse prevention, and mental health.
Phase II Trial Looks to Study Optune's Efficacy in Grade III Recurrent Glioma
Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.
Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM
A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512